Navigation Links
Debiopharm Group Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty
Date:1/13/2014

LAUSANNE, Switzerland, January 13, 2014 /PRNewswire/ --

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, announces that it has completed the recruitment of patients for its Phase III clinical study in Central Precocious Puberty (CPP) with triptorelin 22.5 mg.

Debiopharm is investigating the efficacy and safety of the gonadotropin releasing hormone (GnRH) agonist analog triptorelin pamoate 6-month formulation in the treatment of children suffering from central (GnRH-dependent) precocious puberty (CPP). CPP is defined by pubertal development occurring before the age of 8 years in girls and 9 years in boys, which is not secondary to exposure to sex steroids of adrenal or gonadal origin (peripheral precocious puberty). This 6-month formulation offers an excellent treatment option in a pediatric indication due to less frequent injections. No GnRH agonist 6-month formulation is currently approved for treatment of precocious puberty. The study is an international, multicenter, non-controlled phase III study on the efficacy, pharmacokinetics and safety of two consecutive intramuscular injections of the triptorelin pamoate 22.5 mg 6-month formulation over 12 months. The protocol has gone through the US Food and Drug Administration (FDA) Special Protocol Assessment procedure. The recruitment has been completed and the results are expected in Q4 2014.

"We are very happy to have completed the recruitment in this study," said Eija Lundström, Medical Director responsible for this project at Debiopharm International. "We are looking forward to the results at the end of this year as we believe that the 6-month formulation will simplify the treatment of CPP and make it more tolerable for this young population of patients."


'/>"/>

SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
2. Go To Market Consulting Inc. and Debiopharm Group Collaborate to Identify Early Stage In-licensing Opportunities on the US West Coast
3. Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics
4. Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers
5. Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients
6. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
7. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
8. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
9. Practice Fusion Partners with Healthagens Practice iQ to Help Physician Groups Perform as ACOs
10. Chris Kilbee Appointed Group Director of UBM Pharma Portfolio
11. FDA Warns of Health Complications from Transvaginal Mesh Erosion, Says Life Care Solutions Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... BOSTON , May 29, 2015 /PRNewswire/ ... custom automation, and contract manufacturing, and Vaxxas , ... drug delivery technology, have been named winners of the ... Nanopatch Jet Coating Instrument , an advanced technology platform ... development.  The award was announced last evening at the ...
(Date:5/29/2015)...  Haemonetics Corporation (NYSE: HAE ) announced today ... present at the JMP Securities Life Sciences Conference in ... rd , 2015 at 11:30am Eastern time.  ... via webcast at: http://wsw.com/webcast/jmp27/hae ... a global healthcare company dedicated to providing innovative blood ...
(Date:5/29/2015)... -- Eli Lilly and Company (NYSE: LLY ) and ... have entered into a clinical trial collaboration to evaluate ... immune checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... The planned study will assess the combination as a ... The Phase I study is expected to establish the ...
Breaking Medicine Technology:Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14
... U.S. Food and Drug Administration today advised consumers ... not to use the product. FDA warns that ... active pharmaceutical ingredient sibutramine, a prescription-only drug which ... the product label and could harm consumers, especially ...
... 8 Synapse Biomedical Inc ... U.S. Food and Drug Administration (FDA) designation of the ... Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis ( ... experiencing chronic hypoventilation and has now submitted for Humanitarian ...
Cached Medicine Technology:FDA: Potentially Harmful Stimulant Found in Slimming Beauty Capsules 2Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 2Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 3Synapse Biomedical Receives FDA Humanitarian Use Device Designation for Amyotrophic Lateral Sclerosis (ALS) 4
(Date:5/29/2015)... 2015 A group of doctors have discovered ... national effort to teach this “new math” to children in ... been “sickened” by the recent implementation of Common Core Math ... it, Common Core is now a reality in children’s classrooms ... are now seeking ways to improve common core math training ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw ... the importance of proper sun protection. The print component ... a circulation of approximately 250,000 copies and an estimated ... nationally, through a vast social media strategy, and across ... To explore the digital version of the campaign, ...
(Date:5/29/2015)... 29, 2015 Healthpointe is now ... specialists, physical therapy, and injections , For patients ... and/or lower back pain, Healthpointe has a team ... herniated discs, disc protrusions and other causes of ... Healthpointe’s team of renowned surgeons are now treating ...
(Date:5/29/2015)... Chicago, IL (PRWEB) May 29, 2015 ... is giving patients a long-lasting impression on what ... provider of VisitandCare.com is on a mission to revolutionize ... cosmetic dentistry with a high-class Wellness & Spa. ... of the world’s most successful medical tourism agencies ...
(Date:5/29/2015)... May 29, 2015 As spring has ... Metro series outdoor saunas have increased in popularity as ... and work at summer cottages. While a perennial ... in summer projects a few weeks earlier than usual. ... with smaller lot sizes tend to prefer the Patio ...
Breaking Medicine News(10 mins):Health News:Doctors Discover a Cure for the Common Core 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2
... therapy (ECT) helps patients with severe depression who don't ... often in the earlier stages of the illness, ... ,"Electroconvulsive therapy has been shown to be ... persistent and severe depression, bipolar disorder, and schizophrenia," writes ...
... sudden outbreak of disease has claimed a tenth of Idahos ... fish food and labor. , The outbreak of ... in southwestern Idaho- the state Department of Fish and Game ... the region and official say that it probably resulted when ...
... Monday opposed introduction of sex education in Kashmir schools ... ,Addressing a media conference here, Asiya Andrabi, the DeM ... nefarious Indian designs to perpetuate obscenity and vulgarity in ... schools." ,Andrabi, branded as a hardliner, said ...
... in regard to doctor-patient ratio in various State Government ... varies from case to case depending upon various factors ... of patient-care required i.e. indoor/outdoor. According to the Medical ... works out to 1:1722. ,The patient ...
... company Advanced Cell Technology, is obviously thrilled with ... repair arteries and regenerate blood. , According to ... proceed on to hearts and arteries of ... have devised a straightforward way to make blood vessel precursor ...
... are 73557. There are 22273 numbers of doctors at ... on March 2006. As on 1.1.2007, total numbers of beds ... beds are available in urban government hospitals including Community Health ... of CHCs are located in government buildings. As on March ...
Cached Medicine News:Health News:Despite Being Effective Electroconvulsive Therapy is Underused for Severe Depression 2Health News:Disease Outbreak Claims Trout From Idaho Hatchery 2Health News:Hemangioblasts Aiding Eye Damage Repair 2
... Disc is a Hand Assisted Laparoscopic Surgery ... the surgeons hand may facilitate the procedure, ... has applications in colorectal, urological and general ... extracorporeal extension of pneumoperitoneum and abdominal access ...
... SleepStyle 200 series offers a range ... models. The design delivers therapy to ... features promote results in commercial and ... strongest differentiator in the SleepStyle 200 ...
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
... S6 Lightweight II CPAP has sound ... that maintains consistent pressure. The backlit ... the settings easy, and the interface ... adjustments is simple. This CPAP device ...
Medicine Products: